Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 8/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.52 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrogen Peroxide SCHEMBL2353767 | 0.92 | SLC18A3 (0.64) | SLC18A3SIGMAR1AKR1C3AKR1C1GRIN2B | |
| SCHEMBL6237341 | 0.90 | SLC18A3 (0.52) | SLC18A3SIGMAR1CYP2D6SMN1; SMN2CYP1A2 | |
| SCHEMBL41763 | 0.89 | — | — | |
| SCHEMBL190417 | 0.89 | SLC18A3 (0.67) | SLC18A3SIGMAR1AKR1C3AKR1C1GRIN2B | |
| SCHEMBL5926988 | 0.88 | SLC18A3 (0.55) | SLC18A3SIGMAR1CYP2D6CYP2C19SMN1; SMN2 | |
| Methyl Alcohol SCHEMBL2329914 | 0.86 | SLC18A3 (0.58) | SLC18A3SIGMAR1AKR1C3AKR1C1GRIN2B | |
| Benzene SCHEMBL23070411 | 0.86 | SLC18A3 (0.64) | SLC18A3SIGMAR1AKR1C3AKR1C1GRIN2B | |
| Ammonia Solution, Strong SCHEMBL3932661 | 0.86 | SLC18A3 (0.64) | SLC18A3SIGMAR1AKR1C3AKR1C1GRIN2B | |
| Hydrochloric Acid SCHEMBL29241797 | 0.86 | SLC18A3 (0.64) | SLC18A3SIGMAR1AKR1C3AKR1C1GRIN2B | |
| Bicarbonate SCHEMBL7573346 | 0.84 | AKR1C3 (0.63) | SLC18A3SIGMAR1AKR1C3AKR1C1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2021-09-09 | — | — | US | disclosed |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-9493478-B2 | Fused ring compound containing furan or salt thereof and pharmaceutical composition comprising same | YUHAN CORPORATION (KR) | 2016-11-15 | — | — | US | disclosed |
| US-20160257673-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2016-09-08 | — | — | US | disclosed |
| US-9259426-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150191478-A1 | FUSED RING COMPOUND CONTAINING FURAN OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | YUHAN CORPORATION (KR) | 2015-07-09 | — | — | US | disclosed |
| EP-2876109-A1 | FUSED RING COMPOUND CONTAINING FURAN OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Yuhan Corporation (KR) | 2015-05-27 | — | — | EP | disclosed |
| US-20090285782-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2008009078-A2 | 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR4A1 | SLC18A3 3123/4885SIGMAR1 57/4885AKR1C3 209/4885 |
| US-20150191478-A1 | FUSED RING COMPOUND CONTAINING FURAN OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | PIK3CD, PIK3CA, MTOR | SLC18A3 3446/4885SIGMAR1 3669/4885AKR1C3 2199/4885 |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR4A1 | SLC18A3 3123/4885SIGMAR1 57/4885AKR1C3 209/4885 |
| US-20090285782-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR5A2, NR4A1 | SLC18A3 3179/4885SIGMAR1 70/4885AKR1C3 339/4885 |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR5A2 | SLC18A3 2963/4885SIGMAR1 57/4885AKR1C3 314/4885 |
| US-20160257673-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR5A2 | SLC18A3 2963/4885SIGMAR1 57/4885AKR1C3 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.